Skip to main content
  • US-India Strategic Partnership Forum Extends Support for Indias COVID Crisis Response

    US-India Strategic Partnership Forum and members appreciate the efforts by leaders across the U.S. government at the highest level to identify concrete steps the United States can take to assist India through this crisis. The company looks forward to announcements soon that will support India’s efforts to fill needs like oxygen, medicines, medical supplies, and vaccines. This should include a waiver of current restrictions on the export of vaccine raw materials to ensure production of vaccine in India can continue uninterrupted.

  • Evobrutinib is the First and Only BTK Inhibitor for Multiple Sclerosis

    Merck, a leading science and technology company, will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology Annual Meeting showing that the investigational Bruton’s tyrosine kinase inhibitor evobrutinib significantly reduced blood neurofilament light chain  evels, a key biomarker of neuronal damage and inflammation, in patients with multiple sclerosis (MS).

  • Bioflavonoids Used in Citrobioshield Effectively Control Coronavirus in ICU and Wards

    The fresh surge in COVID-19 cases has now confirmed that the second wave of the coronavirus pandemic is here and is expanding its footprints in India. The study by the Centre for Cellular and Molecular Biology (CCMB) and CSIR-Institute of Microbial Technology (I M Tech) proved the presence of Coronavirus in air samples in Covid-19 wards of hospitals.

  • High Liver Fat (Hepatic Steatosis) Linked to Increased Risk of Hospitalization in COVID-19 Patients With Obesity

    New research published this month in Frontiers in Medicine (Gastroenterology) reveals that individuals with both obesity and severe fatty liver are five times more likely to require hospitalization for the illness. The non-invasive liver imaging technology — Perspectum’s LiverMultiScan — was used to gather MRI scans for the study.

  • Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

    Takeda announced that the European Medicines Agency (EMA) has accepted the Company’s filing packages for its dengue vaccine candidate (TAK-003) which is being investigated for the prevention of dengue due to any dengue virus serotype in individuals ages four to 60. Takeda intends to submit regulatory filings in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka and Thailand during 2021.

  • Masimo EMMA Portable Capnograph useful for assessment of the respiratory condition in children

    Masimo announced the findings of an observational, retrospective study published in Pediatrics International. In the study, researchers at the Osaka Women’s and Children’s Hospital in Japan found the Masimo EMMA® Portable Capnograph “useful for assessment of the respiratory condition in children with tracheostomy.” EMMA® provides seamless mainstream capnography for patients of all ages in a compact, easily portable device.

  • Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies

    Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire Maverick Therapeutics, Inc. a private biopharmaceutical company pioneering conditionally active bispecific T-cell targeted immunotherapies.

  • Galderma Continues Global Growth Ambition With Sculptra® (injectable poly-L-lactic Acid) Re-launch in Europe

    Galderma announced a European re-launch of Sculptra® (injectable poly-L-lactic acid) - a collagen stimulator - with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients. Sculptra® can now be used immediately following a two-minute reconstitution and with the optional addition of lidocaine for patient comfort. Previously, healthcare professionals had to wait two hours following reconstitution to administer the product.

  • Olympus may acquire Israeli Medical Device Company Medi-Tate

    Olympus made its initial investment in Medi-Tate in November 2018, under an agreement that included the rights to distribute Medi-Tate products and gave Olympus an option to acquire 100% of the Israeli company at a later date. Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the minimally invasive treatment of benign prostatic hyperplasia (“BPH”). The company’s flagship product “iTind” has received a European CE mark and is FDA cleared for use in the U.S.

  • Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan

    Takeda Pharmaceutical Company Limited announced that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. Earlier this month, Takeda completed enrollment in the company’s Phase 1/2 immunogenicity and safety study of Moderna’s COVID-19 vaccine candidate (TAK-919) in Japan.

Subscribe to Business Wire India

Search this website